Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.7K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.7K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.5K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.5K
Chemical Synapses01:26

Chemical Synapses

10.7K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
10.7K
Chemical Synapses01:26

Chemical Synapses

3.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
3.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

90
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
90

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case Series.

Advances in therapy·2026
Same author

A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.

Expert review of neurotherapeutics·2025
Same author

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.

The Lancet. Neurology·2025
Same author

Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series.

BMC neurology·2025
Same author

Spinal Muscular Atrophy Update in Best Practices: Recommendations for Treatment Considerations.

Neurology. Clinical practice·2024
Same author

Incidence of Dravet Syndrome in a US Population.

Pediatric neurology briefs·2016

Related Experiment Video

Updated: Nov 23, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.6K

Prognosis in Pediatric Myasthenia Gravis.

Jena Krueger1

  • 1Division of Pediatric Neurology, Helen DeVos Children's Hospital, Grand Rapids, MI.

Pediatric Neurology Briefs
|December 30, 2020
PubMed
Summary

This study reviewed pediatric myasthenia gravis patients diagnosed before age 16. It analyzed clinical characteristics and treatment outcomes in this young patient population.

Area of Science:

  • Neurology
  • Pediatrics
  • Immunology

Background:

  • Myasthenia gravis (MG) is a rare autoimmune neuromuscular junction disorder.
  • Pediatric MG (diagnosed before 16 years) presents unique diagnostic and management challenges.
  • Understanding early-onset MG is crucial for improving long-term patient outcomes.

Purpose of the Study:

  • To retrospectively analyze the clinical features, diagnosis, and treatment of pediatric myasthenia gravis.
  • To identify factors influencing disease progression and treatment response in young patients.
  • To provide insights for optimizing care strategies for children with MG.

Main Methods:

  • Retrospective chart review of patients diagnosed with myasthenia gravis before the age of 16.
  • Data collection included demographics, clinical presentation, diagnostic methods, treatments, and outcomes.
Keywords:
Myasthenia AntibodyMyasthenia Gravis PrognosisPediatric Myasthenia Gravis

More Related Videos

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

10.3K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.6K

Related Experiment Videos

Last Updated: Nov 23, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.6K
Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

10.3K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.6K
  • Analysis focused on identifying patterns and trends in pediatric MG.

    • Main Results:

    • The study identified specific demographic and clinical profiles of pediatric MG.
    • Treatment responses and adverse events were documented.
    • Long-term outcomes and disease trajectories were assessed.

    Conclusions:

    • Pediatric myasthenia gravis exhibits distinct characteristics requiring tailored management approaches.
    • Early diagnosis and appropriate treatment are vital for favorable outcomes in children with MG.
    • Further research is warranted to refine therapeutic strategies for early-onset autoimmune neuromuscular disorders.